Compare AFRM & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFRM | DGX |
|---|---|---|
| Founded | 2012 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3B | 23.2B |
| IPO Year | 2020 | 1996 |
| Metric | AFRM | DGX |
|---|---|---|
| Price | $70.98 | $227.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 13 |
| Target Price | $84.52 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 3.7M | 928.9K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.82% |
| EPS Growth | ★ 108.98 | 13.78 |
| EPS | 0.90 | ★ 2.24 |
| Revenue | $3,224,412,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $30.78 | $7.53 |
| Revenue Next Year | $23.95 | $3.77 |
| P/E Ratio | ★ $79.12 | $101.73 |
| Revenue Growth | ★ 38.80 | 11.78 |
| 52 Week Low | $42.10 | $165.78 |
| 52 Week High | $100.00 | $237.78 |
| Indicator | AFRM | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 69.99 |
| Support Level | $66.21 | $186.40 |
| Resistance Level | $79.10 | N/A |
| Average True Range (ATR) | 3.08 | 5.18 |
| MACD | -1.69 | 0.62 |
| Stochastic Oscillator | 2.29 | 86.79 |
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.